Unexpected Neurological Symptoms of Ruxolitinib: A Case Report

Overview

Journal J Hematol

Specialty Hematology

Date 2020 Nov 23

PMID 33224394

Authors

Francesca Furia

Maria P Canevini

Augusto B Federici

Maria C Carraro

Affiliations

Soon will be listed here.

Abstract

Ruxolitinib is a highly potent inhibitor approved for the treatment of myelofibrosis (idiopathic or post-polycythemia vera or post-essential thrombocythemia) and, more recently, for polycythemia vera with an inadequate response to or intolerant of hydroxyurea. The most common adverse events of ruxolitinib include immunosuppression with an increased risk of reactivation of silent infections and increased non-melanoma skin cancer. The known neurological side effects of ruxolitinib are dizziness and headache, but no neurological paroxysmal episodes have been recorded. This report deals with an 80-year-old outpatient woman with polycythemia vera turned into myelofibrosis who experienced neurological episodes of hypoesthesia and weakness of right arm and leg during ruxolitinib treatment.

References

Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R . Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069. PMC: 5986069. DOI: 10.1038/s41375-018-0077-1. View

Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H . A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol. 2009; 148(6):961-3. DOI: 10.1111/j.1365-2141.2009.08019.x. View

Vannucchi A, Kiladjian J, Griesshammer M, Masszi T, Durrant S, Passamonti F . Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015; 372(5):426-35. PMC: 4358820. DOI: 10.1056/NEJMoa1409002. View

SantAntonio E, Bonifacio M, Breccia M, Rumi E . A journey through infectious risk associated with ruxolitinib. Br J Haematol. 2019; 187(3):286-295. DOI: 10.1111/bjh.16174. View

Sekhar M, McVinnie K, Burroughs A . Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013; 162(6):730-47. DOI: 10.1111/bjh.12461. View

Verstovsek S, Vannucchi A, Griesshammer M, Masszi T, Durrant S, Passamonti F . Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica. 2016; 101(7):821-9. PMC: 5004461. DOI: 10.3324/haematol.2016.143644. View

Tremblay D, Mascarenhas J . Novel Therapies in Polycythemia Vera. Curr Hematol Malig Rep. 2020; 15(2):133-140. DOI: 10.1007/s11899-020-00564-7. View

Cerquozzi S, Tefferi A . Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J. 2015; 5:e366. PMC: 4670948. DOI: 10.1038/bcj.2015.95. View

Tefferi A . Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol. 2008; 83(6):491-7. DOI: 10.1002/ajh.21183. View

10.

Harrison C, Kiladjian J, Al-Ali H, Gisslinger H, Waltzman R, Stalbovskaya V . JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012; 366(9):787-98. DOI: 10.1056/NEJMoa1110556. View

11.

Tremblay D, King A, Li L, Moshier E, Coltoff A, Koshy A . Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis. Leuk Lymphoma. 2019; 61(3):660-667. PMC: 7771191. DOI: 10.1080/10428194.2019.1688323. View

12.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C . Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350(2):114-24. DOI: 10.1056/NEJMoa035572. View

13.

Tefferi A . Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012; 87(3):285-93. DOI: 10.1002/ajh.23135. View

14.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D . Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2012; 368(1):22-33. DOI: 10.1056/NEJMoa1208500. View